Clinical trials: Orthopedic Disorder of Spine
Degenerative Spondylolisthesis
Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion
Ankasa Regenerative Therapeutics, Inc. (Ankasa) is developing ART352-L, a liposomal formulation of recombinant human Wnt3A protein, that is applied ex vivo, to harvested autologous bone grafts (autograft) to enhance the…
- Trial name
- NCT04378543
- Testing
- ART352-L
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ankasa Regenerative Therapeutics, Inc.